Bloomberg News 
(12/7, Cortez) reports, "Lantus [insulin glargine], the world's top-selling insulin with $4.7 billion in annual revenue, more than doubled the risk of developing cancer among people with diabetes," according to research presented at the San Antonio Breast Cancer Symposium. After examining "medical records of 23,266 patients in southern Sweden," researchers found that "diabetics who used Lantus had a 2.9-fold greater chance of cancer, while those who took the generic drug metformin had an eight percent lower risk."
No comments:
Post a Comment